Home - International News - Novo Nordisk’s next obesity drug falls short of Lilly rival, wiping billions off its market value By Syndication Editor Feb 23, 2026 Novo Nordisk’s next obesity drug falls short of Lilly rival, wiping billions off its market value International News 5 Total views No comments Syndication Editor Related Posts Is It Ever Too Late To Catch Up on Retirement Savings? Vanguard Plans for Its Most Expensive ETFs Yet in Active Push Comments (No) Leave a Reply Cancel Reply Save my name, email, and website in this browser for the next time I comment. Hide Comments
Comments (No)